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Summary
Objective: The objective of this study was to determine the role of nitric oxide (NO) in tumor necrosis factor alpha (TNF-a)-induced matrix
damage, compared to interleukin 1 beta (IL-1b), in bovine cartilage explant cultures.
Methods: Cartilage explants were subjected to treatment with TNF-a (100 ng/ml), IL-1b (10 ng/ml) and to the nitric oxide synthase inhibitor,
N-methyl-arginine (L-NMA; 1.25 mM) for 26, 50 or 120 h (5 days). The collected medium was analyzed for sulfated glycosaminoglycan
(sGAG), nitrate and nitrite, matrix metalloproteinase (MMP) activity by zymography, and aggrecan degradation by immunoblotting of aggre-
can-G1 and aggrecan-G1-NITEGE fragments. RNAwas extracted from the 26 and 50 h treated explants for real time quantitative PCR analyses.
Results: TNF-a and IL-1b treatment caused a 3e5 fold increase in sGAG release with an increase in aggrecanase-speciﬁc aggrecan break-
down and an increase in nitrate and nitrite production. L-NMA treatment inhibited almost 50% of the sGAG release caused by TNF-a treatment,
with concomitant decrease in the aggrecanase-speciﬁc-NITEGE neo-epitope of aggrecan released into the medium. No L-NMA effect was
identiﬁed with IL-1b. TNF-a and IL-1b both increased a disintegrin and matrix metalloproteinase with thrombospondin motif (ADAMTS)4
and ADAMTS5 transcription with no effect by L-NMA, suggesting that NO regulates aggrecanase activity at a post-transcriptional level in re-
sponse to TNF-a. TNF-a and IL-1b both caused an increase in protease transcription (MMP-3, MMP-13, ADAMTS4 and ADAMTS5) and in
pro-inﬂammatory enzymes, inducible nitric oxide synthase and cyclooxygenase (COX)-2, as well as a decrease in matrix protein transcription,
including collagen II, aggrecan, fibromodulin and link protein (IL-1b only), and an increase in MMP-3 and MMP-9 secretion. L-NMA had no
effect on gene transcription or MMP secretion.
Conclusion: NO regulates aggrecanase activity at a post-transcriptional level in response to TNF-a treatment while having no effect on IL-1b
treated cartilage explants.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Nitric oxide (NO) is a neutral free radical product of nitric
oxide synthase (NOS) with potent biological effects through
its actions on cyclic-guanidine monophosphate (cGMP)
production as well as through various oxidative and nitrosa-
tive chemistries that have been shown to modulate gene
expression and to alter protein structure and function1.
NO production by chondrocytes was ﬁrst discovered by
Stadler et al. who showed that, in vitro, chondrocytes pro-
duce substantial amounts of NO in response to interleukin1This research was funded in part by NIH grants AR45779 and
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4891 beta (IL-1b) and to lipopolysaccharide (LPS)2. Since
these ﬁrst reports, numerous studies have shown that chon-
drocytes or cartilage explant cultures from most species
produce NO via inducible nitric oxide synthase (iNOS) in re-
sponse to IL-1b, IL-1a, LPS, and tumor necrosis factor
alpha (TNF-a)3,4, as well as IL-17, IL-18, interleukin 1 con-
verting enzyme (ICE), and ﬁbronectin fragments5e7.
The inﬂammatory cytokines TNF-a and IL-1 contribute to
disease processes in rheumatoid arthritis (RA) and likely in
osteoarthritis (OA). TNF-a was identiﬁed in synovial exu-
dates of RA and OA joints8,9. In RA patients, TNF-a may
contribute to IL-1 production as determined by anti-
TNF-a therapy10, and TNF-a alone or in combination with
IL-1 may cause cartilage breakdown and a decrease in
new matrix synthesis by chondrocytes in vitro11. TNF-a pro-
duction by OA synovial cells and in synovial ﬂuid and serum
may be elevated in OA10,12,13, and OA cartilage explants
may be more sensitive to IL-1 and TNF-a treatment14e16.
TNF-a receptor, TNF-R p55, is elevated in chondrocytes
490 A. L. Stevens et al.: NO enhances TNF-a-induced aggrecan lossnear OA lesions, and this expression correlates with sul-
fated glycosaminoglycan (sGAG) depletion17. These data
together suggest that TNF-a as well as IL-1 may play
a role in cartilage breakdown in OA.
To determine whether NO production plays a role in
mediating the pro-catabolic and anti-anabolic effects of in-
ﬂammatory mediators, in vitro studies have used the NOS
inhibitors, L-NMA (L-N-methyl-arginine), Nu-nitro-L-arginine
methyl ester (L-NAME), aminoguanidine, and L-NIO
(N-iminoethyl-L-ornithine), to evaluate the role of NO in IL-1-
induced changes in chondrocyte metabolism and matrix
degradation in explant, hydrogel, and monolayer culture.
With the exception of bovine explant studies18, inhibiting
NOS partially reversed IL-1-induced inhibition of proteogly-
can synthesis in cartilage explants or chondrocyte cul-
tures4,19,20. TNF-a can decrease proteoglycan synthesis
in a NO dependent manner21, and the exogenous NO
donor, S-nitroso-N-acetyl-1,1-penicillamine (SNAP), may
also decrease proteoglycan synthesis. Cao et al. found
that NO decreased collagen synthesis22. Studies on matrix
degradation have shown that inhibiting NO production may
enhance18,23,24 or have no effect25 on IL-1b-induced aggre-
can degradation as measured by sGAG release. IL-1-in-
duced NO was also found to enhance gelatinase2,26,27
and alter stromelysin (MMP-3)18,26 expression or activity.
While most studies on inhibition of NOS are associated
with IL-1 treatment, other inﬂammatory cytokines, such as
TNF-a, are capable of mediating cartilage damage and en-
hancing NO production. Thus, understanding the contribu-
tions of NO with other cytokines may be important in
determining their role in cartilage degradation.
The purpose of this study was to characterize the role of
NO in matrix degradation in response to TNF-a and com-
pare it to the effects of NO following IL-1b treatment using
a non-speciﬁc NOS inhibitor, L-NMA. We found that inhibi-
tion of NOS by L-NMA decreased sGAG release in re-
sponse to TNF-a by almost 50%, with a concomitant
decrease in release of aggrecan-G1-NITEGE fragments
speciﬁc for aggrecanase-mediated aggrecan degradation.
No L-NMA effect was seen with IL-1b treatment. L-NMA
did not alter a disintegrin and matrix metalloproteinase
with thrombospondin motif (ADAMTS)4 or ADAMTS5 tran-
scription in response to cytokine treatment. Gene transcrip-
tion proﬁling of a panel of inﬂammatory molecules,
proteases, and matrix proteins showed that TNF-a and IL-
1b both inhibited transcription of matrix proteins including
collagen II, aggrecan, link protein, and ﬁbromodulin, while
enhancing matrix proteases and inﬂammatory factors
such as MMP-3, MMP-13, iNOS, and cyclooxygenase
(COX)-2, all with no effect of L-NMA. Overall these data sug-
gest that NO plays a role in TNF-a-induced aggrecan re-
lease at a post-transcriptional level by altering ADAMTS4
or ADAMTS5 protein expression or post-translational mod-
iﬁcation, and that TNF-a and IL-1b appear to promote
aggrecan degradation through different mechanisms of
aggrecanase regulation.MethodsREAGENTSInsulin, transferrin, and selenium (ITS) medium supplement and NOS inhib-
itor, NMA,were fromSigma (St Louis, MI, USA). Recombinant human IL-1b and
TNF-a were from R&D systems (Minneapolis, MN, USA), polyacrylamide gel
electrophoresis (PAGE) gels were from BioRad (Hercules, CA, USA). Prote-
ase-free chondroitinase and keratanase II were from Seikagaku (Japan).
Common chemicals were purchased from ICN (Irvine, CA), Mallenkrodt (Hazel-
wood, MO), or Sigma (St. Louis, MO).CARTILAGE EXPLANT HARVEST AND CULTUREArticular cartilage disks were obtained from the patello-femoral groove of
1e2 week old bovine calves as described previously28. Cartilage-bone
cylinders (9-mm diameter) were cored from the patello-femoral groove, per-
pendicular to the joint surface. Two 1-mm-thick slices were then microtomed
from the middle zone and a 6-mm diameter dermal punch was then used to
core a 6-mm diameter by 1-mm-thick disk from the center of each of the 9-
mm slice. The explants were cultured in high glucose Dulbecco’s modiﬁed
eagle’s medium (DMEM) with 1% ITS as described previously with medium
change every other day prior to treatment29. Explants were weighed 2 days
prior to the start of cytokine treatment.TNF-a, IL-1b, AND L-NMA TREATMENTSCartilage explants were allowed to rest 7 days in culture, and were then
treated with 10 ng/ml IL-1b or 100 ng/ml TNF-a or left untreated in 2 ml of
medium without 1% ITS. After 2 h, half the explants were further treated
with 1.25 mM L-NMA. Experiments utilized 5e8 different joints (5e8 different
animals) with at least two explants per joint per condition. Every 24 h over 5
days, cultures underwent a 10% (200 ml) medium removal and supplementa-
tion. After day 5 of treatment, medium and explants were collected, pooled to
each treatment group, and stored at 80C. For real time PCR analyses
explants were cultured for 24 or 48 h after the addition of L-NMA and snap
frozen in liquid nitrogen.sGAG ASSAYsGAG released to the medium was measured as an indicator of aggrecan
degradation and assessed via the dimethylmethylene blue (DMMB) assay
using shark chondroitin C as a standard, as described previously30.NITRATE/NITRITE ANALYSISMedium samples were diluted 1:2 in water prior to nitrate and nitrite anal-
ysis by Griess assay31. Total nitrogen oxides were determined by cadmium
column reduction of nitrate to nitrite followed by direct nitrite detection by Gri-
ess reaction. Nitrite was assayed directly, and nitrate was calculated as the
difference between the total nitrogen oxides and nitrite.GELATIN AND CASEIN ZYMOGRAPHY FOR MMPsZymograms were performed as described32. Brieﬂy, conditioned medium
from day 5 was mixed with 4 non-reducing sodium dodecyl sulfate (SDS)-
sample buffer and electrophoresed in 10%/12% gelatin or casein zymogram
gels. Proteases were renatured in 2.5% triton X-100 solution, and placed in
solution of 50 mM Tris and 5 mM CaCl2 for 18 h at 37
C. Gels were then
ﬁxed and stained with Coomassie brilliant blue and destained until bands be-
came visible and distinct. Ethylenediamine tetraacetic acid (EDTA) was
added to the incubation buffer to verify MMP activity. MMP-3 and MMP-9
were veriﬁed by immunoblot.DESALTING AND DEGLYCOSYLATIONSamples were desalted by ethanol precipitation or by dialysis with deglyco-
sylation. The medium equivalent of 10e20 mg sGAG was precipitated by the
addition of three volumes of ice-cold ethanol. The samples were resuspended
(50 mM TriseAcetate, 10 mM EDTA) and sequentially deglycosylated begin-
ning with 5 mU of protease-free chondroitinase ABC for 3 h followed by
0.1 mU of keratanase II and 0.1 mU of endo-b-galactosidase for an additional
4 h. Equal amounts of sGAG were loaded for aggrecan Western blots.WESTERN BLOT ANALYSISConcentrated samples (10e15 ml) were subjected to denaturing sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on
a 4e15% gradient gel run at 15 mA for 2 h. Proteins were then transferred
to Immobilon polyvinylidene ﬂuoride (PVDF) membrane, and proteins were
detected using a monoclonal antibody to the aggrecan-NITEGE neo-epitope
in the interglobular domain of aggrecan associated with aggrecanase degra-
dation (from C. Flannery, Wyeth Pharmaceuticals, Madison, NJ).RNA EXTRACTION AND REAL TIME PCRFor each condition (untreated, L-NMA, TNF-a L-NMA, IL-1b L-NMA),
2e3 cartilage explants per condition per joint, from a total of eight joints (eight
animals) were taken at 26 and 50 h of culture, pulverized under liquid nitrogen
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Fig. 1. Five-day accumulated total nitrate and nitrite release to the
medium(nmol/mg wetweight) asameasureofNOproduction plotted
as mean S.E.M. from greater than three explants per joint pooled
from ﬁve different joints (animals) (*P< 0.001 cytokine compared
to control and **P< 0.01 cytokine compared to cytokineþNMA).
491Osteoarthritis and Cartilage Vol. 16, No. 4and homogenized in Trizol (Invitrogen, San Diego, CA, USA). As described
previously33, homogenates were transferred to Phase Gel tubes according
to the manufacturer’s instructions (Eppendorf, Hamburg, Germany) and
spun at 10,000 rpm for 10 min at 4C. The clear RNA containing
supernatant was removed from Phase Gel tubes and subjected to RNAeasy
mini-kit clean-up (Qiagen, Chatsworth, CA, USA) according to manufacturer’s
instructions. RNA quantiﬁcation was determined by nano-drop method mea-
suring absorbance at 260 nm and 280 nm, which gave the concentration of
RNA extracted from the tissue and the purity of the extract; the average
260/280 absorbance ratio for all samples was 2.12 0.1. Equal amounts of
RNA were subjected to reverse transcription using AmpliTaq-Gold reverse
transcription kit (ABI, Foster City, CA, USA) to generate cDNA for real time
PCR analysis. Real time PCR analysis was performed with Applied Biosys-
tems SYBR-Green master mix in combination with cDNA and primers, using
the ABI prism 7900HT real time 384-well plate PCR instrument. Both forward
and reverse primers were designed using Primer3 software based on the bo-
vine genomic sequence33. Primers from 32 genes relevant to cartilage homeo-
stasis were used: 18S-RNA, aggrecan, collagen II, ﬁbromodulin, ﬁbronectin,
proteoglycan link protein, MMP-1, MMP-3, MMP-9, MMP-13, ADAMTS4,
ADAMTS5, tissue inhibitor of metalloproteinase (TIMP)-1, TIMP-2, TIMP-3,
COX-2, iNOS, glyceraldehyde-3-phosphate dehydrogenase (G3PDH),
b-actin, insulin-like growth factor (IGF)-1, IGF-2, transforming growth factor
(TGF)-b, TNF-a, IL-1b, IL-4, IL-6, thioredoxin inhibitor protein (TXNIP), heat
shock protein (HSP)90, CD44, hyaluronic acid synthetase (HAS)2, basic ﬁbro-
blast growth factor (bFGF), and osteogenic protein -1 (OP-1). Standard curve
analysis was performed on each primer to determine the efﬁciency of ampliﬁ-
cation and proper primer concentration. The measured cycle threshold (CT)
was determined and converted to relative copy number using information
from standard curves for comparisons.DATA ANALYSIS AND STATISTICSReal time PCR data for each gene were ﬁrst normalized to 18S-RNA;
data from each sample were then normalized to the untreated control sam-
ple within each sample set (animal), and these normalized data were
pooled across all animals and are reported as the mean S.E.M. (n¼ 8)
for each condition. Principal component analysis and k-means clustering
were performed on the PCR data using components of the Matlab Statistics
toolbox33. Cluster analysis was performed33 on a (31 5 2) matrix of
data derived from the set of 31 genes (i.e., all genes but 18S), ﬁve treat-
ment conditions (each normalized to untreated control), and two time points
(26 or 50 h). Each time point was also clustered individually to test the
robustness of the co-expressed gene groupings. The KruskaleWallis test
and Wilcoxon Sign Rank test with Bonferroni correction for multiple com-
parisons were used to determine statistical signiﬁcance of the L-NMA effect
and of pair-wise comparisons between treatments, respectively. For the
sGAG and nitrate/nitrite assays, multi-way analysis of variance (ANOVA)
followed by a post-hoc Student’s t test with Bonferroni correction for multi-
ple comparisons were used to determine statistical signiﬁcance deﬁned as
P< 0.05. All statistical analyses were performed using Matlab (Natick, MA,
USA) or Systat 11 (Richmond, CA, USA).25
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Griess assay as described by Green et al.31 IL-1b and
TNF-a both increased accumulated nitrate and nitrite com-
pared to the untreated control (P< 0.001) (Fig. 1). The rela-
tive amounts of nitrite and nitrate were similar between the
two cytokine treatments by day 5 (data not shown). Treatment
of samples with L-NMA inhibited NO production to levels at or
near untreated controls.sGAG RELEASE0 1 2 3 4 5
Time (days)
Fig. 2. Accumulated sGAG release to medium over 5-day cytokine
treatment in the presence or absence of L-NMA plotted as mean
S.E.M. IL-1b and TNF-a alone cause a 3e5 fold increase in sGAG
release compared to untreated controls (P< 0.001 for all points).
L-NMA inhibited roughly half the sGAG release caused by treatment
with TNF-a (P< 0.01 for all time points).sGAG loss, which is known to be predominantly the result
of aggrecan degradation in cartilage explants, was measured
by DMMB assay. TNF-a and IL-1b caused 3e4 fold increase
in sGAG release to the medium compared to control samples
(Fig. 2; P< 0.001 for TNF-a and IL-1b compared to controls
at all time points). Treatment with L-NMA partially inhibited
TNF-a-induced sGAG release (P< 0.003 for all time points).
However, with the exception of the 24 h time point, L-NMAhad no effect on IL-1b-induced sGAG release (P¼ 0.015
for ﬁrst 24 h; P> 0.745 for all other points). No L-NMA effect
was seen in the absence of cytokine treatment. These
results suggest that NO was partially responsible for sGAG
release in response to TNF-a treatment, but had little or no
effect on IL-1b treatment.WESTERN ANALYSIS FOR AGGRECANASE GENERATED
AGGRECAN-G1 NEO-EPITOPETo investigate whether L-NMA was able to decrease
sGAG release by decreasing aggrecanase-mediated prote-
olysis of aggrecan, immunoblots were performed to probe
the aggrecan-NITEGE-COOH neo-epitope generated by
aggrecanase activity (Fig. 3). A 60e80 kDa band was visi-
ble in the TNF-a and IL-1b treated lanes but not in the
untreated (control) lanes of the immunoblot. While the addi-
tion of L-NMA to IL-1b treatment had no effect on the anti-
NITEGE-stained band, samples treated with TNF-a and
L-NMA showed a marked decrease compared to the sample
treated with TNF-a alone. This result suggests that the
75 kDa
TNF-α
NMA+-+-+-
--++--
IL-1β++----
Fig. 3. Anti-aggrecan-G1-NITEGE-COOH Western blot to probe
mechanism of sGAG loss in response to IL-1b and TNF-a treatment
with and without NOS inhibitor, L-NMA. A band is visualized in
all cytokine-treated conditions; however, the TNF-a þ L-NMA
band is signiﬁcantly lighter than that with TNF-a alone or with
IL-1b L-NMA. This immunoblot is representative of ﬁve different
experiments and corresponding blots.
492 A. L. Stevens et al.: NO enhances TNF-a-induced aggrecan lossdecrease in sGAG release seen with the addition of L-NMA
to TNF-a treatment was related to decreased aggrecanase-
speciﬁc proteolysis of aggrecan.ZYMOGRAPHY FOR METALLOPROTEINASE MEASUREMENTSTo examine MMP expression and activity, zymography
was performed on medium samples at the end of the exper-
iment. Samples subjected to IL-1b treatment and, to a lesser
extent, TNF-a treatment showed a diffuse clearing contain-
ing a doublet between 50 kDa and 75 kDa (with the lower
band most prominent) by casein zymography [Fig. 4(A)],
representing secreted pro-MMP-3. No activated MMP-3
band (at 45 kDa) was visible in any of the samples. Gelatin75 kDa
100 kDa
100 kDa
75 kDa
50 kDa
- - + + - - IL-1β
- - - - + + TNF-α
- + - + - + NMA
- - + + - - IL-1β
- - - - + + TNF-α
- + - + - + NMA
50 kDa
A
B
Fig. 4. Casein (A) and Gelatin (B) zymograms of 5-day culture me-
dium. (A) The casein zymogram for both IL-1b and IL-1beL-NMA
contains a 54 kDa band, corresponding to pro-MMP-3 that appears
as a doublet, with a lighter upper band and a brighter lower band. A
faint doublet is seen for TNF-a treatment and, in addition, a 90 kDa
band is seen with all cytokine treatments. (B) The gelatin zymogram
contained a 72 kDa band (arrow) and a lower 65 kDa band in all
samples, corresponding to the pro- and active forms of MMP-2,
respectively. Only cytokine-treated samples had a 92 kDa band
corresponding to MMP-9. L-NMA had no effect on MMP-3, MMP-9
or MMP-2 expression or activation as seen in medium samples.zymography [Fig. 4(B)] demonstrated two bands running in
between 75 kDa and 50 kDa in all samples, which represent
the pro- and the active forms of MMP-2. In addition,
a w90 kDa band indicative of pro-MMP-9 was present
only in the cytokine-treated samples. No differences in
MMP-2, MMP-3, or MMP-9 were seen with L-NMA treat-
ment, as assessed by zymography.REAL TIME PCR ANALYSESTo determine whether cytokine L-NMA treatments
altered transcription of aggrecanases, other proteases,
matrix molecules, cytokines, and growth factors, real time
PCR analysis of a 32-gene set was performed on explants
from eight different animals subjected to 26 and 50 h of IL-
1b or TNF-a treatment L-NMA, or L-NMA alone. Relative
copy numbers were normalized to 18S-RNA and expressed
in terms of the fold increase or decrease compared to
untreated control samples within each set. Expression of
both ADAMTS4 and ADAMTS5 was elevated in response
to TNF-a and IL-1b treatment (though little increase at
50 h for ADAMTS5), with no statistically signiﬁcant effect
of added L-NMA at either the 26 h or the 50 h time point
[Fig. 5(A)]. To elucidate the main expression patterns and
identify groups of genes co-expressed under different treat-
ment conditions, gene clustering was performed. The re-
sults are shown in principal component space (Fig. 6); the
ﬁrst three principal components accounted for w95% of
the variance in the data. k-means clustering (31 genes,
ﬁve normalized conditions, two time points) showed that
the genes segregated well into two spatially distinct groups
with group centroids as indicated (Fig. 6). The centroid pro-
ﬁles (showing each condition for each group) are repre-
sented in Fig. 5(B,C) as the mean S.E.M. of each
centroid. Group 1 genes [Fig. 5(B)] had little response or
were slightly down-regulated by IL-1b and TNF-a treatment,
while Group 2 genes were up-regulated by IL-1b and TNF-a
[Fig. 5(C)]. For each individual gene in Groups 1 and 2,
the average-fold-change S.E.M. is listed in Table I (with
TNF-a and IL-1b each compared to control, TNF-a com-
pared to TNF-aþ L-NMA, and IL-1b compared to
IL-1bþ L-NMA); asterisks represent statistical signiﬁcance
for the comparison (P< 0.05). While addition of L-NMA
often slightly decreased gene transcription compared to
IL-1b or TNF-a alone, this decrease was not statistically sig-
niﬁcant for any individual gene.Discussion
IL-1b and, to a lesser extent, TNF-a, can induce chondro-
cyte-mediated matrix degradation, with loss of aggrecan
typically preceding collagen degradation34. Previous stud-
ies explored the role of NO in IL-1b-induced aggrecan deg-
radation; however, to our knowledge, this is the ﬁrst study to
test the effect of NO on TNF-a-induced sGAG release and
to explore its underlying mechanism. Cartilage explants
treated with the NOS inhibitor, L-NMA, showed marked inhi-
bition of TNF-a-induced sGAG release and concomitant
production of aggrecan-G1-NITEGE fragments, indicating
a decrease in aggrecan proteolysis by aggrecanase. In con-
trast, L-NMA did not alter IL-1b-induced sGAG release or
the generation of aggrecan-G1-NITEGE fragments. Real
time PCR analyses showed no signiﬁcant effect of L-NMA
alone on expression of ADAMTS4 or ADAMTS5 or a panel
of 30 other matrix genes, proteases and cytokines. To-
gether, these results suggest that NO plays a role in the
R
el
at
iv
e 
ex
pr
es
sio
n 
le
ve
l
0
1
2
3
4
5
NMA TNF-α TNF-α +
NMA
IL-1β IL-1β +
NMA 
C
R
el
at
iv
e 
ex
pr
es
sio
n 
le
ve
l
0
0.4
0.8
1.2
NMA TNF-α TNF-α +
NMA
IL-1β IL-1β +
NMA 
B Group1
Group 2
* * *
*
R
el
at
iv
e 
ex
pr
es
sio
n 
le
ve
l
A
0.1
1
10
100
NMA TNF-α TNF-α +
NMA
IL-1β IL-1β +
NMA
* * *
* * ** *
ADAMTS4 - 26hr
ADAMTS4 - 50hr
ADAMTS5 - 26hr
ADAMTS5 - 50hr
26 hrs
50 hrs
26 hrs
50 hrs
Fig. 5. Relative gene expression by real time PCR and clustering
analyses. (A) Expression of ADAMTS4 and ADAMTS5 at 26 and
50 h time points, relative to controls, in response to treatment
with L-NMA alone, IL-1b L-NMA and TNF-a L-NMA. (B) Centroid
proﬁle for gene cluster 1 (Group 1 genes) which showed decreased
expression or was unchanged in response to cytokine treatment.
Centroids represent 26 and 50 h time points clustered together.
(C) Centroid proﬁle for gene cluster 2, showing genes that were
up-regulated in response to cytokine treatment. (Groups produced
from clustering 26 h alone (see Table I) vs 26 and 50 h together
were identical, except IGF-2 and TIMP-3 in Table I swapped
groups.) The * indicates statistical signiﬁcance compared to the un-
treated control sample by pair-wise comparison (Wilcoxon Sign
Rank test with Bonferroni correction for multiple comparison;
P< 0.05).
493Osteoarthritis and Cartilage Vol. 16, No. 4post-transcriptional regulation of aggrecanases in response
to TNF-a, while NO has no effect on IL-1b-induced aggre-
can degradation. Thus, TNF-a and IL-1b utilize different
pathways of expression or activation of aggrecanases to
mediate aggrecanolysis, with that of TNF-a being regulated
in part by a NO mediated post-transcriptional processing of
ADAMTS4 and ADAMTS5.NO can mediate its effects through enhancing cGMP, in-
creasing protein nitrosation or protein nitration which may
serve as an important regulatory mechanism at the level
of the cell or individual proteins. NO concentration and
chemistry, which depend in part on oxygen free radicals,
may determine its role as a second signal mediator. Treat-
ment of cartilage with cytokines caused an increase in NO
production (Fig. 1; P< 0.001 for IL-1b and TNF-a vs control
for both nitrate and nitrite). In addition, TNF-a or IL-1b
resulted in similar amounts of nitrate and nitrite, each corre-
sponding to approximately half of the NO production, sug-
gesting that NO chemistry was similar for both cytokine
treatments. L-NMA decreased NO to control levels for
both cytokines (cytokineþ L-NMA vs control not signiﬁcant).
Equal nitrate and nitrite production with both TNF-a and
IL-1b treatment suggests that the effects of NO likely
depend on cellular processes induced with each cytokine
treatment and not NO chemistry.
The role of NO in matrix degradation associated with TNF-
a may be quite different than that with IL-1b. In this study,
L-NMA treatment inhibited TNF-a-induced sGAG loss by
w50% (Fig. 2). While we know of no previous reports of
the effects of NO treatment with TNF-a alone, van Bezooijen
et al.35 showed no measurable effect of L-NMA on cartilage
damage induced by the combination of TNF-a and IL-17,
compared to the cytokine combination alone as assessed
by Alcian blue staining for sGAG. We found that L-NMA
had no effect on sGAG loss following IL-1b treatment
(Fig. 2), similar to the ﬁndings of Bird et al.25 using equine car-
tilage explants. In contrast, Stefanovic-Racic found that
L-NMA in the presence of IL-1b signiﬁcantly increased
sGAG release compared to IL-1b alone, using bovine,
human, and rabbit explants18,23. Regarding other matrix
degrading signals, Pichika et al.36 showed that inhibiting
NO resulted in a matrix protective effect when cartilage
was treated with ﬁbronectin fragments, similar to the effect
seenwith TNF-a (Fig. 2). The effects of NOappear to depend
on the cytokines or other signals with which it is produced
and with which it signals. NO appears to play a distinctly
degradative role in TNF-a (but not in IL-1b) treated cartilage.
Because aggrecanases are known to mediate aggrecan
degradation in response to IL-1b and TNF-a37,38, we hypoth-
esized that the mechanism of L-NMA inhibition of
TNF-a-induced sGAG release was through a decrease in
aggrecanase cleavage of aggrecan at the Glu373eAla374
site in the interglobular domain37,39. Immunoblot analysis
of the medium using an antibody to the aggrecan-
NITEGE373 fragment showed that L-NMAþ TNF-a resulted
in less fragment release than TNF-a alone (Fig. 3), consistent
with decreased sGAG release (Fig. 2), and while L-NMA did
not alter sGAG release induced by IL-1b, there was no de-
crease in aggrecan-NITEGE373 fragment release either.
These results suggest that NO is partially responsible for
TNF-a-induced aggrecanase activity in cartilage explants.
While aggrecanases are the main mediator of aggreca-
nolysis early in response to IL-1b and TNF-a treatment,
NO has also been implicated in the activation of MMPs
through the disruption of the cysteine switch present in
the zymogens40. Therefore, zymography was used to eval-
uate the effects of L-NMA on the expression and activation
of selected MMPs in response to cytokine treatment. IL-1b
(and to a lesser extent, TNF-a) increased pro-MMP-3 secre-
tion to the medium with no effect of L-NMA on activation or
secretion [Fig. 4(A)]. Pro-MMP-9 was expressed in re-
sponse to cytokine treatment, while MMP-2 was present
under all conditions. L-NMA had no effect on MMP-2 or
MMP-9 secretion or activation. MMP-3 and MMP-9 proteins
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Fig. 6. Projection plot of gene behavior represented by the ﬁrst three principal components. The genes readily separated into two clusters
which correspond to genes that respond positively to IL-1b and TNF-a treatment (triangles; Group 2 of Table I) and those genes that either
did not respond or responded negatively to the cytokine treatment (squares; Group 1). The black circles indicate the group centroids which are
signiﬁcantly different from each other (P< 0.001; Student’s t test).
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(Figs. 5 and 6; Table I). These zymography results were
also similar to those of Dozin et al.41, who saw no effect
of NOS inhibition on MMPs with chondrocyte monolayers
treated with IL-1a and TNF-a in combination. Zymography
failed to show evidence of an active MMP-3 band and no
effect of L-NMA was observed, suggesting NO mediates
aggrecan degradation in response to TNF-a by enhancing
aggrecanase and not MMP-3 activity.
While ADAMTS1, 8, 9, 15, 16, and 18 have aggrecanase
activity42,43, only ADAMTS4 and ADAMTS5 are known to
potently cleave the Glu373eAla374 site forming the aggre-
can-NITEGE fragment44. We thus focused on ADAMTS4
and ADAMTS5 to explore the possible mechanism by which
NO may be mediating an increase in aggrecanase activity.
Because ADAMTS4 and ADAMTS5 proteins could not be
reliably identiﬁed in tissue or medium samples (data not
shown), we examined the effects of NO inhibition on gene
expression of ADAMTS4 and ADAMTS5 as well as a panel
of genes associated with cartilage homeostasis (Table I).
We hypothesized that changes in expression of aggreca-
nases in response to cytokine and L-NMA treatments would
likely occur approximately 24 h before sGAG release to the
medium, allowing time for protein expression and diffusion
of aggrecan fragments out of the tissue. Since the rate of
sGAG release was maximal between days 2 and 4 of treat-
ment (Fig. 2), real time PCR analysis was performed on
explants at 26 and 50 h after treatment with IL-1b or TNF-a
L-NMA. While IL-1b and TNF-a treatment caused signiﬁcant
changes in gene expression of many of the genes tested in-
cluding ADAMTS4 and ADAMTS5 (Fig. 5; Table I), L-NMA
treatment did not alter transcription of any genes evaluated
in this study at either 26 or 50 h.Previous studies using young bovine explants showed
signiﬁcant increases in transcription of ADAMTS4 after
24 h of treatment with IL-1a45 and IL-1b46, while ADAMTS5
was up-regulated by TNF-a46. Here, we observed a strong
increase in ADAMTS5 expression with TNF-a and IL-1b at
26 h but little increase at 50 h [Fig. 5(A)]. In contrast,
ADAMTS4 showed a sustained increase in expression at
26 and 50 h with both IL-1b and TNF-a [Fig. 5(A)]. Interest-
ingly, while TNF-a caused a greater average increase in
ADAMTS4 and ADAMTS5 transcription than IL-1b (Table I),
IL-1b treatment resulted in greater sGAG release. In addi-
tion, L-NMA did not signiﬁcantly alter transcription of either
ADAMTS4 or ADAMTS5 in response to either cytokine
treatment. Thus, the NO mediated regulation of ADAMTS4
and/or ADAMTS5 activity in response to TNF-a is likely
post-transcriptional and may be at the level of either trans-
lation or post-translational modiﬁcation such as proteoly-
sis45. ADAMTS4 and ADAMTS5 do undergo proteolysis,
which is known to change its binding afﬁnity and proteolytic
speciﬁcity of aggrecan cleavage sites44,45,47. Although less
is known about ADAMTS5, some work on ADAMTS4 sug-
gests that its activity may be regulated in part through
a combination of proteolysis and/or proteineprotein inter-
actions rather than by protein expression45,48,49. Further
work to explore the role of NO in modulating possible
ADAMTS4 activators or inhibitors may be warranted. While
it is possible that NO could play a more direct role in
ADAMTS4 and/or ADAMTS5 activity through direct chemi-
cal modiﬁcation, this would still require a difference in
ADAMTS4 and ADAMTS5 protein expression between
TNF-a and IL-1b in order to explain a TNF-a speciﬁc NO
effect. But based on our ﬁndings, changes in aggrecanase
transcription cannot account for the effects of L-NMA on
Table I
Genes probed by real time PCR, represented as the mean fold-change over control S.E.M. at 26 h. Groups were determined using clustering
analysis of data from the 26 h time point. The expression data for the individual genes show similar trends at the 50 h time point. The
* indicates statistical significance compared to the untreated control sample by pair-wise comparison (Wilcoxon Sign Rank test with
Bonferroni correction for multiple comparison; P< 0.05). Data represent experiments from eight animals with two or three explants pooled
per animal for RNA extraction
Gene NMA TNF-a TNF-a/TNFþNMA IL-1b IL-1b/IL-1bþNMA
Group 1
Aggrecan 0.98 0.06 0.74 0.07* 1.17 0.14 0.91 0.05 1.12 0.24
Collagen II 0.98 0.13 0.73 0.11 1.14 0.27 0.81 0.10 1.31 0.19
Fibromodulin 1.18 0.12 0.59 0.06* 0.98 0.08 0.86 0.06 0.91 0.05
Link protein 1.0 0.10 0.46 0.06* 0.95 0.07 0.81 0.08 1.09 0.15
TIMP-2 0.99 0.12 0.53 0.03* 1.12 0.16 0.50 0.08* 0.76 0.12
TIMP-3 0.61 0.11 1.1 0.37 4.07 3.18 0.97 0.27 1.52 0.53
MMP-1 0.88 0.09 0.92 0.08 1.02 0.10 0.98 0.09 1.15 0.08
G3DPH 0.90 0.12 0.72 0.15 0.93 0.21 0.89 0.19 0.82 0.16
b-Actin 0.95 0.08 0.81 0.06 0.92 0.05 0.86 0.07 1.03 0.07
IGF-1 1.0 0.13 0.50 0.12* 1.05 0.21 0.64 0.10 1.33 0.27
IL-4 0.82 0.11 0.78 0.11 1.10 0.26 0.91 0.13 1.27 0.23
IL-6 0.77 0.13 0.82 0.15 1.56 0.38 1.1 0.16 1.33 0.30
TXNIP 0.92 0.09 0.55 0.05* 0.87 0.09 0.66 0.05* 0.91 0.06
HAS2 1.0 0.12 0.49 0.03* 0.95 0.11 0.47 0.04* 1.01 0.12
Group 2
Fibronectin 0.96 0.08 1.60 0.15* 1.16 0.10 1.41 0.15* 1.20 0.16
MMP-3 1.0 0.18 11 2.7* 1.75 0.43 34 9.1* 1.80 0.53
MMP-9 1.1 0.24 115 60 1.11 0.24 74 54 0.79 0.17
MMP-13 0.83 0.17 12 4.4* 1.87 0.66 76 23* 1.31 0.17
ADAMTS4 0.98 0.09 8.0 1.1* 1.24 0.16 5.9 1.4* 1.26 0.14
ADAMTS5 1.26 0.23 68 9.1* 1.28 0.24 17.4 6.9* 1.15 0.17
TIMP-1 10.1 0.16 4.6 1.3* 1.40 0.38 3.4 0.64* 1.24 0.19
COX-2 1.2 0.11 11.4 2.7* 1.13 0.20 17.6 5.0* 1.28 0.27
NOS2 1.5 0.57 4513 1495* 1.04 0.31 894 183* 1.94 0.70
IGF-2 0.99 0.10 0.92 0.08 0.94 0.17 1.1 0.11 0.96 0.11
TGF-b 0.92 0.07 2.3 0.20 0.91 0.06 1.7 0.18* 1.10 0.08
TNF-a 2.0 0.98 2.5 1.6 0.91 0.13 3.7 2.6 1.27 0.22
IL-1b 0.95 0.12 4.4 2.8 1.35 0.25 4.3 2.4 1.33 0.34
HSP90 0.85 0.07 2.2 0.27* 1.21 0.11 1.3 0.14 1.06 0.08
CD44 1.0 0.17 20 3.0* 1.06 0.09 11 2.1* 1.27 0.16
bFGF 9.0 7.0 1722 1109 10.56 5.86 61 48 8.66 4.91
OP-1 1.6 0.41 80 16* 1.32 0.28 26 10* 1.42 0.31
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effects of L-NMA between IL-1b and TNF-a.
While previous studies have not reported changes in ex-
pression via qPCR for the broad panel of genes examined
here (Table I), we note several useful comparisons. Sasaki
et al. reported a NO dependent increase in bFGF and
MMP-9 gene expression by rabbit chondrocytes in mono-
layer in response to IL-1b50. While we did ﬁnd an increase
in the mean transcription level of bFGF and MMP-9 at 26
and 50 h with TNF-a and IL-1b (not statistically signiﬁcant),
no L-NMA effect was observed. In the present study, iNOS,
responsible for chondrocyte production of NO, was elevated
in response toboth IL-1bandTNF-a (P< 0.05), aswasCOX-2,
MMP-3, andMMP-13 but not IL-6 orMMP-1. With the excep-
tion of IL-6 and MMP-1, these ﬁndings were consistent with
the reported effects of IL-1b on human chondrocytes51 and
effects on MMPs in human OA cartilage using TNF-a and
IL-1b receptor inhibitors52 as well as equine cartilage in
response to TNF-a53. Decreases in matrix gene expression
(e.g., collagen II, aggrecan, fibromodulin, and link protein)
were more pronounced at 50 h than at 26 h suggesting
that effects of IL-1b and TNF-a on matrix gene expression
may occur later compared to the up-regulation of matrix de-
grading enzymes54 (P< 0.05, TNF-a and IL-1b compared
to control for collagen alpha 1(II), aggrecan, ﬁbromodulin,
and link protein (IL-1 only) at 50 h). The inhibitory effect of
IL-1b and TNF-a on aggrecan and collagen synthesis is
well characterized.In summary, NO plays an enhancing role in TNF-a (but
not IL-1b)-induced aggrecanase-mediated aggrecan degra-
dation. Inhibiting NO production with L-NMA caused no
changes in ADAMTS4 or ADAMTS5 gene transcription;
however, L-NMA partially inhibited aggrecanase-mediated
aggrecan degradation in response to TNF-a suggesting
that NO must play a role in regulating aggrecanases at
a post-transcriptional level. At the same time, inhibiting
NOS had no detectable effects on IL-1b or TNF-a-induced
MMP expression, activation, or the gene expression of
various other matrix proteins, cytokines or growth factors
after 26 or 50 h of cytokine treatment. IL-1b and TNF-
a-enhanced transcription of inﬂammatory genes such as
iNOS and COX-2 as well as matrix degrading enzymes
MMP-3 and MMP-13 at 26 h, and both cytokines decreased
collagen II, aggrecan, link protein and ﬁbromodulin at 50 h,
consistent with known effects of these cytokines and with
no effect of L-NMA. These ﬁndings support the hypothesis
of a post-transcriptional role for NO in regulating aggreca-
nase activity in response to TNF-a treatment, and the hy-
pothesis that TNF-a and IL-1b regulate aggrecanase
activity though different mechanisms.Acknowledgements
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